An interventional study of early transcriptomic markers in Obesity & Overweight, sponsored by University Hospital, Clermont-Ferrand. Not yet recruiting at 1 site in France. Open to participants aged 1 Day to 4 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-21.
Sponsored by University Hospital, Clermont-Ferrand · Not applicable, Interventional, and Screening
Among 44 studies in Obesity by University Hospital, Clermont-Ferrand — 6 open to participants now, 6 under way, none of them phase 3. Obesity · University Hospital, Clermont-Ferrand.
Among the 44 studies in Obesity by University Hospital, Clermont-Ferrand, this one is the 4th largest by planned enrollment of the 37 interventional ones that give a count, is one of 3 that started in 2026, is one of 34 with no phase, and was the 44th registered.
11,522 studies on the registry are indexed under Obesity; 2,033 are open to participants now.
Browse Obesity studies →6 of the 44 studies in Obesity by University Hospital, Clermont-Ferrand are open now, in 1 country. Recruiting first, the newest first:
University Hospital, Clermont-Ferrand · Sites in France
Ages 18–90
University Hospital, Clermont-Ferrand · Sites in France
Ages 18–80
University Hospital, Clermont-Ferrand · Sites in France
Ages 18–40 · Women only
University Hospital, Clermont-Ferrand · Sites in France
Ages 18–60 · Women only
University Hospital, Clermont-Ferrand · Sites in France
Ages 18–70
By country, each count listing its studies:
Of the 1,336 Obesity studies recruiting now, 377 (28%) set no upper age limit and 856 (64%) stop at 75 or younger; 168 take children under 18; 491 take healthy volunteers.
This study: 1 Day to 4 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 400 is above the median of 67 across 9,006 interventional studies indexed under Obesity.
Median enrollment 40 across the 37 interventional studies, 90 across the 7 observational. Of the 23 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
University Hospital, Clermont-Ferrand is the lead sponsor of 859 studies on the registry; 179 are open to participants now.
1 of the studies in Obesity by University Hospital, Clermont-Ferrand that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07120685University Hospital, Clermont-FerrandProof of Concept in the Prevention of Post-bariatric Sarcopenia: Simulated Activation of the "Gravitostat" | 2027-11 |
Among the 44 studies in Obesity by University Hospital, Clermont-Ferrand, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Metabolic diseases, including childhood obesity, represent a major public health challenge. Studies in mice have identified transcriptomic markers in adipose tissue capable of predicting a predisposition to obesity prior to any weight gain. The MARIOBE project aims to translate this approach to young children (≤ 4 years old) in order to identify individual vulnerability to obesity at an early stage.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other: early transcriptomic markers
during a scheduled surgery before the age of 4 years, collection of a blood sample (2.5 mL in a PAXgene tube) and two adipose tissue fragments, each measuring 5 mm x 5 mm x 5 mm. tracking of weight and height curves from birth to age 6
transcriptomic markers in children under 4 years of age that predict a predisposition to being overweight at age 6 (BMI > IOTF25).
Ranking of the discriminative capacity of adipocyte and blood transcripts before 4 years of age to predict the development of overweight (BMI \> IOTF25) at age 6, using Partial Least Squares Discriminant Analysis (PLS-DA).
Time frame: perioperative
analyze weight trajectories
Selection and validation of transcriptomic markers for the development of a predictive score for the risk of overweight and obesity in children
Time frame: at age 6 years
molecular and epigenetic mechanisms associated with the identified transcriptomic signatures.
methylation profiles
Time frame: at the time of blood ans adipose tissu sampling
comparison of transcriptomic expression levels between blood and adipose tissue
percentage of common markers sampled from blood and adipose tissue
Time frame: perioperative
develop a quantitative test based on digital PCR to define individual expression thresholds predictive of risk
Performance of the digital PCR test evaluated by the ability to discriminate weight trajectories (AUC of ROC curves).
Time frame: at age 6 years
Start is estimated for Sep 2026; primary completion for Sep 2036, 120 months later.
Of 3,680 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 120 months is above that.
Counting every sponsor, half of 3,843 studies reached it within 22 months; a quarter within 10 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Clermont-Ferrand →